Yongkyu Kim
Chief Executive Officer Biomatz
Yongkyu Kim is CEO of Biomatz, a South Korea-based biotech company focused on microbiome therapeutics and live biotherapeutic product development. Under his leadership, Biomatz has built a proprietary platform for designing cooperative microbial consortia to address health and nutrition challenges. The company also explores applications in nutraceuticals and functional foods. Yongkyu brings expertise in microbiome research and biopharmaceutical innovation to drive Biomatz’s mission of advancing next-generation microbiome solutions for global health.
Seminars
Wednesday 28th January 2026
Expanding Indications into Dermatology & Metabolic Disorders to Address Unmet Needs
9:30 am
- Presenting preclinical data on a dual-strain LBP for atopic dermatitis that restores skin barrier function and reduces S. aureus colonisation
- Optimising topical formulation strategies and translational plans for dermatology applications in both human and veterinary models
- Introducing a microbiome-based co-therapy to mitigate GLP-1 side effects in obesity treatment while preserving gut barrier integrity
